EU sees AstraZeneca clot link, but backs use
A top official at the European Medicines Agency says there is a causal link between the AstraZeneca coronavirus vaccine and rare blood clots, but that the connection is unclear and the benefits of taking the shot outweigh the risks of getting COVID-19.
Marco Cavaleri, head of health threats and vaccine strategy at the Amsterdam-based agency, told Rome's Il Messaggero newspaper on Tuesday that the European Union's medicines regulator is preparing to make a more definitive statement on the topic this week.
Asked about Cavaleri's comments, the EMA press office said its evaluation "has not yet reached a conclusion and the review is currently ongoing". It said it planned a news conference as soon as the review is finalized, possibly on late Wednesday.